Biolargo Stock Performance
| BLGO Stock | USD 0.18 0.01 5.26% |
On a scale of 0 to 100, BioLargo holds a performance score of 5. The firm shows a Beta (market volatility) of 1.15, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioLargo will likely underperform. Please check BioLargo's treynor ratio, as well as the relationship between the semi variance and day median price , to make a quick decision on whether BioLargo's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioLargo are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile technical and fundamental indicators, BioLargo displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 716 K | |
| Total Cashflows From Investing Activities | -34 K |
BioLargo |
BioLargo Relative Risk vs. Return Landscape
If you would invest 16.00 in BioLargo on November 4, 2025 and sell it today you would earn a total of 2.00 from holding BioLargo or generate 12.5% return on investment over 90 days. BioLargo is currently generating 0.2688% in daily expected returns and assumes 4.0147% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of otc stocks are less volatile than BioLargo, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLargo Target Price Odds to finish over Current Price
The tendency of BioLargo OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.18 | 90 days | 0.18 | about 50.0 |
Based on a normal probability distribution, the odds of BioLargo to move above the current price in 90 days from now is about 50.0 (This BioLargo probability density function shows the probability of BioLargo OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the otc stock has the beta coefficient of 1.15 suggesting BioLargo market returns are highly reactive to returns on the market. As the market goes up or down, BioLargo is expected to follow. Additionally BioLargo has an alpha of 0.1091, implying that it can generate a 0.11 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). BioLargo Price Density |
| Price |
Predictive Modules for BioLargo
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioLargo. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioLargo Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioLargo is not an exception. The market had few large corrections towards the BioLargo's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioLargo, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioLargo within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 1.15 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.03 |
BioLargo Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioLargo for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioLargo can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioLargo has some characteristics of a very speculative penny stock | |
| BioLargo had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 1.1 M. | |
| BioLargo currently holds about 1.23 M in cash with (3.94 M) of positive cash flow from operations. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Elementos Advances EU-Focused Tin Strategy as Prices Surge and Funding Strengthens - TipRanks |
BioLargo Fundamentals Growth
BioLargo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of BioLargo, and BioLargo fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLargo OTC Stock performance.
| Return On Equity | -3.63 | |||
| Return On Asset | -0.69 | |||
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.16) % | |||
| Current Valuation | 52.87 M | |||
| Shares Outstanding | 275.42 M | |||
| Price To Earning | (4.54) X | |||
| Price To Book | 10.61 X | |||
| Price To Sales | 11.52 X | |||
| Revenue | 2.53 M | |||
| EBITDA | (6.64 M) | |||
| Cash And Equivalents | 1.23 M | |||
| Total Debt | 367 K | |||
| Debt To Equity | 0.72 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.94 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 3.02 M | |||
| Retained Earnings | (89.68 M) | |||
| Current Asset | 1.87 M | |||
| Current Liabilities | 831 K | |||
About BioLargo Performance
By examining BioLargo's fundamental ratios, stakeholders can obtain critical insights into BioLargo's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BioLargo is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.Things to note about BioLargo performance evaluation
Checking the ongoing alerts about BioLargo for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for BioLargo help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLargo has some characteristics of a very speculative penny stock | |
| BioLargo had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 1.1 M. | |
| BioLargo currently holds about 1.23 M in cash with (3.94 M) of positive cash flow from operations. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Elementos Advances EU-Focused Tin Strategy as Prices Surge and Funding Strengthens - TipRanks |
- Analyzing BioLargo's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLargo's stock is overvalued or undervalued compared to its peers.
- Examining BioLargo's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLargo's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLargo's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of BioLargo's otc stock. These opinions can provide insight into BioLargo's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.